- Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice2008 | Central Library of Charles University
- Familial hypercholesterolemia is still unknown?2014 | First Faculty of Medicine
- Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice +12008 | Faculty of Medicine in Hradec Králové
- Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice2008 | First Faculty of Medicine
- ApoE/LDL receptor-double-knockout mice: an animal model for the study of statins effects in atherogenesisPublication without faculty affiliation
- Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice2008 | Faculty of Pharmacy in Hradec Králové
- ApoE/LDL receptor-double-knockout mice: an animal model for study of statins effects in atherogenesisPublication without faculty affiliation
- Modulation of Rat Liver Regeneration after Partial Hepatectomy by Dietary Cholesterol2018 | Faculty of Medicine in Hradec Králové
- Low-density lipoprotein receptor-related protein-5 C/T polymorphism in exon 18 is associated with C peptide and proinsulin levels in control women and patients with polycystic ovary syndrome2008 | First Faculty of Medicine
- The treatment of hypercholesterolemia by PCSK9 inhibitors2014 | Faculty of Medicine in Hradec Králové
- Monoclonal antibodies in the treatment of dyslipidemia and cardiovascular risk reduction2015 | First Faculty of Medicine
- Turn in hypercholesterolemia treatment - PCSK9 inhibitors. What we know about the alirocumab (product Praluent(R)) yet?2016 | First Faculty of Medicine
- Molecular genetics of hypercholesterolemia2016 | First Faculty of Medicine
- Perspectives of further reduction in cholesterol by means of PCSK9 blockade2013 | Faculty of Medicine in Hradec Králové
- New treatment possibilities of homozygous familial hypercholesterolemia2023 | Faculty of Medicine in Hradec Králové
- PCSK9 inhibitors in light of recent data2016 | First Faculty of Medicine
- Evolocumab: lowering of both the LDL cholesterol and cardiovascular risk2015 | First Faculty of Medicine
- Evolocumab - antibody against PCSK9 with a profound lipid-lowering effect2015 | First Faculty of Medicine
- Evolocumab, proproteine convertase subtilisin/kexin type 9 inhibitor for intensive treatment of dyslipidemia2016 | Faculty of Medicine in Pilsen
- Lifelong exposure and trajectories of the risk factors - a new direction in prediction of CVD risk2022 | First Faculty of Medicine
- Low concentration of plasma cholesterol and type 2. diabetes mellitus2021 | First Faculty of Medicine
- On the liver and atherosclerosis2019 | Second Faculty of Medicine
- PCSK-inhibitor in theory, in studies and in the real practice2019 | First Faculty of Medicine
- PCSK9 inhibition as the new hope for patients with familial hypercholesterolemia, statin intolerance and eventually for those at the highest cardiovascular risk? Focused on alirocumab, Praluent(R)2015 | First Faculty of Medicine
- Alirocumab, Praluent(R) in the light of studies2016 | First Faculty of Medicine
- Regulation of intracellular metabolism of LDL-cholesterol: the importance of inhibition of PCSK92014 | Faculty of Medicine in Hradec Králové
- Extracorporeal elimination in familial hypercholesterolemia - comparison of two methods2014 | Faculty of Medicine in Hradec Králové
- Alirocumab2016 | Third Faculty of Medicine
- Několik postřehů ze studie FOURIER s evolocumabem2017 | First Faculty of Medicine
